I
Imara
Dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies
About Imara
Imara Inc. is a biopharmaceutical company focused on developing innovative therapies for patients suffering from rare genetic blood disorders, specifically sickle cell disease and beta thalassemia. The company operates in the healthcare sector, targeting a niche market of individuals affected by these hemoglobinopathies. Imara's core product, IMR 687, is a highly selective, potent small molecule inhibitor of PDE9, designed to be an oral, once-daily treatment that potentially modifies the disease. The business model revolves around the research, development, and commercialization of this therapeutic candidate, aiming to improve patient outcomes and quality of life. Revenue is generated through the sale of IMR 687, once approved, and potentially through partnerships and licensing agreements with other pharmaceutical companies. Imara serves patients, healthcare providers, and broader communities impacted by these rare diseases. The company is also involved in initiatives like the Real Impact Grants Program to support affected individuals and has been recognized by its inclusion in the U.S. Small Cap Russell Index.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Boston, United States
- Listing
- IPO 2020
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 70.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Feb 2023 | — | — | Enliven Therapeutics | ↗ |
| POST IPO EQUITYOther financing | Jul 2021 | $50M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Imara is 1.1K monthly website visits, up 223.5% over the last three months. Imara's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
NEA- BCBay City Capital
Pfizer
Series A6 investors entered at this stage
Alexandria Venture Investments
Lundbeckfonden Ventures
OrbiMed
Arix Bioscience
RA Capital Management
Rock Springs Capital
Other known investors2 additional known investors
Enliven Therapeutics
Lundbeckfonden
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imara on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imara’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.